Federal contract award
75F40121C00133
ENHANCEMENT AND VALIDATION OF IN VITRO - IN VIVO CORRELATION METHOD FOR LONG ACTING INJECTABLE DRUG PRODUCTS TO ACCELERATE THEIR GENERIC DEVELOPMENT
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | FDA OFFICE OF ACQ GRANT SVCS |
| NAICS | 541990 — All Other Professional, Scientific, and Technical Services |
| PSC | AN41 — HEALTH R&D SERVICES; HEALTH CARE - OTHER; BASIC RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST NO FEE |
| Obligations | $1.3M |
| Current contract value | $1.3M |
| Potential contract value / ceiling | $1.3M |
| Start date | Sep 24, 2021 |
| Current end date | Sep 29, 2025 |
| Potential end date | Sep 29, 2025 |
| Latest award activity | Jun 30, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 5 of 5 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jun 30, 2026 | P00004 | $-22.1K | NO COST MODIFICATION TO CHANGE THE PERIOD OF PERFORMANCE END DATE TO SEPTEMBER 29, 2025 |
| Jul 2, 2024 | P00003 | $0 | NO COST MODIFICATION TO CHANGE THE PERIOD OF PERFORMANCE END DATE TO SEPTEMBER 29, 2025 |
| Feb 26, 2024 | P00002 | $116.5K | ENHANCEMENT AND VALIDATION OF IN VITRO - IN VIVO CORRELATION METHOD FOR LONG ACTING INJECTABLE DRUG PRODUCTS TO ACCELERATE THEIR GENERIC DEVELOPMENT |
| Nov 2, 2021 | P00001 | $0 | EO14042 ENHANCEMENT AND VALIDATION OF IN VITRO - IN VIVO CORRELATION METHOD FOR LONG ACTING INJECTABLE DRUG PRODUCTS TO ACCELERATE THEIR GENERIC DEVELOPMENT |
| Sep 24, 2021 | 0 | $1.2M | ENHANCEMENT AND VALIDATION OF IN VITRO - IN VIVO CORRELATION METHOD FOR LONG ACTING INJECTABLE DRUG PRODUCTS TO ACCELERATE THEIR GENERIC DEVELOPMENT |
Buyer contacts from matching notices
Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.
| Contact | Role | Published contact methods | Evidence | Source date |
|---|---|---|---|---|
| Kimberly DeLong | Contact | kimberly.delong@fda.hhs.gov 2404028639 | Source | May 26, 2021 |
| Robert Maydwell | Contact | Robert.Maydwell@fda.hhs.gov 301-348-1814 | Source | May 26, 2021 |
| Kimberly DeLong | Contact | kimberly.delong@fda.hhs.gov 2404028639 | Source | May 26, 2021 |
| Anthony S. Wimbush | Contact | anthony.wimbush@fda.hhs.gov 2404027628 | Source | May 26, 2021 |
| Kimberly DeLong | Contact | kimberly.delong@fda.hhs.gov 2404028639 | Source | Jan 28, 2021 |
| Anthony S. Wimbush | Contact | anthony.wimbush@fda.hhs.gov 2404027628 | Source | Jan 28, 2021 |
| Benjamin Golway | Contact | Benjamin.Golway@fda.hhs.gov 3018374464 | Source | Nov 20, 2020 |
| Anthony S. Wimbush | Contact | anthony.wimbush@fda.hhs.gov 2404027628 | Source | Nov 20, 2020 |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.